| pubmed-article:18846109 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18846109 | lifeskim:mentions | umls-concept:C0007620 | lld:lifeskim |
| pubmed-article:18846109 | lifeskim:mentions | umls-concept:C0431085 | lld:lifeskim |
| pubmed-article:18846109 | lifeskim:mentions | umls-concept:C1366765 | lld:lifeskim |
| pubmed-article:18846109 | lifeskim:mentions | umls-concept:C1710082 | lld:lifeskim |
| pubmed-article:18846109 | lifeskim:mentions | umls-concept:C1704259 | lld:lifeskim |
| pubmed-article:18846109 | lifeskim:mentions | umls-concept:C1705987 | lld:lifeskim |
| pubmed-article:18846109 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:18846109 | pubmed:dateCreated | 2009-2-16 | lld:pubmed |
| pubmed-article:18846109 | pubmed:abstractText | Several advances in recent years have focused increasing attention on the role of the RAF-MEK-ERK1/2 pathway in promoting cell survival. The demonstration that BRAF is a human oncogene mutated at high frequency in melanoma, thyroid and colon cancer has provided a pathophysiological context, whilst the description of potent and highly selective inhibitors of BRAF or MEK has allowed a more informed and rational intervention in both normal and tumour cells. In addition, separate studies have uncovered new mechanisms by which the ERK1/2 pathway can control the activity or abundance of members of the BCL-2 protein family to promote cell survival. It is now apparent that various oncogenes co-opt ERK1/2 signalling to de-regulate these BCL-2 proteins and this contributes to, and even underpins, survival signalling in some tumours. New oncogene-targeted therapies allow direct or indirect inhibition of ERK1/2 signalling and can cause quite striking tumour cell death. In other cases, inhibition of the ERK1/2 pathway may be more effective in combination with other conventional and novel therapeutics. Here, we review recent advances in our understanding of how the ERK1/2 pathway regulates BCL-2 proteins to promote survival, how this is de-regulated in tumour cells and the opportunities this might afford with the use of new targeted therapies. | lld:pubmed |
| pubmed-article:18846109 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18846109 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18846109 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18846109 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:18846109 | pubmed:issn | 1476-5403 | lld:pubmed |
| pubmed-article:18846109 | pubmed:author | pubmed-author:CookS JSJ | lld:pubmed |
| pubmed-article:18846109 | pubmed:author | pubmed-author:BalmannoKK | lld:pubmed |
| pubmed-article:18846109 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18846109 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:18846109 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18846109 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18846109 | pubmed:pagination | 368-77 | lld:pubmed |
| pubmed-article:18846109 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:meshHeading | pubmed-meshheading:18846109... | lld:pubmed |
| pubmed-article:18846109 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:18846109 | pubmed:articleTitle | Tumour cell survival signalling by the ERK1/2 pathway. | lld:pubmed |
| pubmed-article:18846109 | pubmed:affiliation | Laboratory of Molecular Signalling, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK. kathy.balmanno@bbsrc.ac.uk | lld:pubmed |
| pubmed-article:18846109 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18846109 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:18846109 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18846109 | lld:pubmed |
